These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37813601)

  • 21. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
    Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the renin-angiotensin-aldosterone system in heart failure.
    Lang CC; Struthers AD
    Nat Rev Cardiol; 2013 Mar; 10(3):125-34. PubMed ID: 23319100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.
    de Abajo FJ; Rodríguez-Martín S; Lerma V; Mejía-Abril G; Aguilar M; García-Luque A; Laredo L; Laosa O; Centeno-Soto GA; Ángeles Gálvez M; Puerro M; González-Rojano E; Pedraza L; de Pablo I; Abad-Santos F; Rodríguez-Mañas L; Gil M; Tobías A; Rodríguez-Miguel A; Rodríguez-Puyol D;
    Lancet; 2020 May; 395(10238):1705-1714. PubMed ID: 32416785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel potassium binders as enabling therapy in heart failure.
    Butler J; Khan MS; Anker SD
    Eur J Heart Fail; 2019 May; 21(5):550-552. PubMed ID: 30993820
    [No Abstract]   [Full Text] [Related]  

  • 29. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction.
    Kocabaş U; Ergin I; Kıvrak T; Yılmaz Öztekin GM; Tanık VO; Özdemir İ; Avcı Demir F; Doğduş M; Şen T; Altınsoy M; Üstündağ S; Urgun ÖD; Sinan ÜY; Uygur B; Yeni M; Özçalık E
    ESC Heart Fail; 2023 Dec; 10(6):3677-3689. PubMed ID: 37804042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
    Buysse JM; Huang IZ; Pitt B
    Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation.
    Su J; Barbe F; Houël R; Guyene TT; Crozatier B; Hittinger L
    Basic Res Cardiol; 1999 Apr; 94(2):128-35. PubMed ID: 10326661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Adherence to Renin-Angiotensin System Inhibitors and β-Blockers After Heart Failure Hospitalization in Senior Patients.
    Qin X; Hung J; Teng TK; Briffa T; Sanfilippo FM
    J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):531-540. PubMed ID: 32500739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Independent Association Between Use of Proton Pump Inhibitors and Muscle Wasting in Patients with Heart Failure: A Single-Center, Ambispective, Observational Study.
    Ohori K; Yano T; Katano S; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Kouzu H; Koyama M; Nagano N; Fujito T; Nishikawa R; Ohwada W; Furuhashi M
    Drugs Aging; 2023 Aug; 40(8):731-739. PubMed ID: 37328671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure.
    Tsutamoto T; Sakai H; Tanaka T; Fujii M; Yamamoto T; Wada A; Ohnishi M; Horie M
    Circ J; 2007 Jun; 71(6):915-21. PubMed ID: 17526990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
    Cleland JG; Morgan K
    Curr Opin Cardiol; 1996 May; 11(3):252-62. PubMed ID: 8835867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
    Sarwar CMS; Bhagat AA; Anker SD; Butler J
    Handb Exp Pharmacol; 2017; 243():537-560. PubMed ID: 28382468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.